gdc
Financial SupportMultiple MyelomaSupport Services

Financial Support Services for Patients with Multiple Myeloma

The following financial support services are available for patients with multiple myeloma. For more information, see the full 2018 Patient Guide to Cancer Support Services.
April 2018 Vol 4 No 2

Patient access to cancer therapies can present a serious challenge because of the high cost of many cancer drugs, and the cost continues to rise. Whether you are insured, underinsured, or uninsured, many drug companies now offer help in the form of free medication or reduced cost of their medications for patients who cannot afford them. These programs are designed specifically to help you pay for your medications to ensure that you receive the best treatment you need.

In addition, many national organizations and foundations, as well as government programs, offer patients financial assistance with their medications. For more information on these programs visit www.conquer-magazine.com/pssguide2018.

Below is the list of drugs that are approved by the FDA for multiple myeloma, and the financial support services offered by the respective companies.

Darzalex (daratumumab)

Drug company: Janssen Biotech
844-553-2792

Darzalex is a human CD38-directed monoclonal antibody used, alone or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, for the treatment of multiple myeloma in patients who received at least 1 previous therapy; or with pomalidomide and dexamethasone for patients who received at least 2 previous therapies, including lenalidomide and a proteasome inhibitor (PI); or as monotherapy in patients who received at least 3 previous therapies, including a PI and an immunomodulatory drug (IMiD), or who are double-refractory to a PI and an IMiD.

Janssen offers 2 financial assistance programs for patients using Darzalex:

Janssen CarePath Savings Program

With this program, privately insured patients will pay just $5 for the first 8 infusions of Darzalex, and $10 for each additional infusion, with a $15,000 maximum annual benefit.

Johnson & Johnson Patient Assistance Foundation

This program provides Darzalex free of charge for up to 12 months to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Doxil (doxorubicin hydrochloride liposome injection)

Drug company: Janssen
877-227-3728

Doxil is an anthracycline topoisomerase II inhibitor used for the treatment of patients with multiple myeloma, in combination with bortezomib, after at least 1 previous therapy that was not bortezomib.

Janssen offers 1 financial assistance program for patients using Doxil:

Johnson & Johnson Patient Assistance Foundation

This program provides Doxil free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Empliciti (elotuzumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Empliciti is a SLAMF7-directed immunostimulatory antibody used, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma.

Bristol-Myers Squibb (BMS) Access Support offers 2 financial assistance programs for patients using Empliciti:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Empliciti. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Empliciti, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $35,640 for an individual or $48,060 for a family of 2.

Farydak (panobinostat)

Drug company: Novartis
800-245-5356

Farydak is a histone deacetylase inhibitor used, in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Farydak:

Novartis Oncology Universal Co-Pay Card

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Farydak for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Farydak for free for 1 year, or until a prescription drug coverage becomes available to them.

Kyprolis (carfilzomib)

Drug company: Amgen
888-427-7478

Kyprolis is a proteasome inhibitor used for the treatment of patients with relapsed or refractory multiple myeloma, as a single agent or in combination with dexamethasone or with lenalidomide plus dexamethasone, after 1-3 therapies.

Amgen offers 3 financial assistance programs for patients using Kyprolis:

Kyprolis FIRST STEP Program

For privately insured patients whose insurance covers Kyprolis, this program ensures a patient copay of $0 for the first dose, and $25 for each dose thereafter, with a maximum benefit of $20,000 per patient per calendar year.

Amgen Assist 360

Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for the medication.

Amgen Safety Net Foundation

EQualified, uninsured patients can receive Kyprolis for free through Amgen’s nonprofit program, the Safety Net Foundation.

Mozobil (plerixafor)

Drug company: Sanofi Genzyme
888-847-4877

Mozobil is a hematopoietic stem-cell mobilizer used, in combination with granulocyte colony-stimulating factor, for the treatment of patients with multiple myeloma.

The Sanofi Patient Connection offers 1 financial assistance program for patients using Mozobil:

Sanofi Patient Assistance Connection

Patients who are uninsured or whose insurance does not cover Mozobil can apply for financial assistance through this program. Eligible patients must have an annual household income of no more than 500% of the current poverty level. Patients with Medicare Part D can apply if they are not eligible for Low Income Subsidy and have out-of-pocket drug costs that equal 5% or more of their annual income.

Ninlaro (ixazomib)

Drug company: Takeda Oncology
844-617-6468

Ninlaro is a proteasome inhibitor used , in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma.

Takeda Oncology, through Ninlaro 1Point, offers 3 financial assistance programs for patients using Ninlaro:

Ninlaro Co-Pay Assistance Program

Patients with private insurance can pay as little as $25 per prescription for up to 13 prescription refills annually, with a maximum benefit value of $25,000 annually.

Ninlaro RapidStart Program

This program provides a 1-cycle supply of Ninlaro for patients with Medicare Part D coverage or private insurance who experience a delay in insurance coverage determination of at least 7 days.

Ninlaro Patient Assistance Program

Patients without prescription drug or health insurance coverage may qualify to receive free medication through this program.

Pomalyst (pomalidomide)

Drug company: Celgene
800-931-8691

Pomalyst is a thalidomide analog used, in combination with dexamethasone, for the treatment of patients with multiple myeloma who have received at least 2 previous therapies.

Celgene Patient Support offers 3 financial assistance programs for patients using Pomalyst:

Celgene Commercial Co-pay Program

This program reduces the copay for Pomalyst to $25 or less, for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Pomalyst for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Revlimid (lenalidomide)

Drug company: Celgene
800-931-8691

Revlimid is a thalidomide analog used for the treatment of patients with multiple myeloma, in combination with dexamethasone, and as maintenance therapy after autologous hematopoietic stem-cell transplant.

Celgene Patient Support offers 3 financial assistance programs for patients using Revlimid:

Celgene Commercial Co-pay Program

This program reduces the copay for Revlimid to $25 or less, for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Revlimid for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Thalomid (thalidomide)

Drug company: Celgene
800-931-8691

Thalomid is a thalidomide used, in combination with dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma.

Celgene Patient Support offers 3 financial assistance programs for patients using Thalomid:

Celgene Commercial Co-pay Program

This program reduces the copay for Thalomid to $25 or less, for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria may be able to receive Thalomid for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Velcade (bortezomib)

Drug company: Takeda Oncology
866-835-2233

Velcade is a proteasome inhibitor used for the treatment of patients with multiple myeloma.

Takeda Oncology offers 2 financial assistance programs for patients using Velcade:

Velcade Reimbursement Assistance Program

For patients with Medicare, Medicaid, or private insurance, this program will help find supplemental coverage if needed and provide assistance with copays.

Velcade Patient Assistance Program

Patients without insurance coverage may qualify to receive their medication free of charge through this program. Patient eligibility is based on household income, treatment setting, and medically appropriate need.

Recommended For You
Multiple Myeloma
Sparking a Cure for Multiple Myeloma
By Brian McMahon
After being a caregiver to his mother in her battle with multiple myeloma, Brian McMahon launched SparkCures to help patients with this cancer find the right clinical trials.
Multiple Myeloma
A Message to Patients with Multiple Myeloma
By Yelak Biru
Yelak Biru notes that there are many resources and support groups that can help patients with multiple myeloma and provides some words of encouragement.
Multiple Myeloma
What Do You Wish You Had Known Upon Diagnosis?
By Yelak Biru
Yelak Biru discusses his experience in gathering information when he was diagnosed with multiple myeloma in 1995 versus the information landscape today, and addresses what he wishes he had known at the time.
Clinical TrialsMultiple Myeloma
Patient Misconceptions About Clinical Trials
By Yelak Biru
Yelak Biru identifies some pervasive misconceptions and common barriers that exist regarding clinical trials.
Last modified: April 18, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country